公开(公告)号：US11744896B2

公开(公告)日：2023-09-05

申请号：US17488080

申请日：2021-09-28

Applicant: Creighton University ,  ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (Tennessee not for profit corporation)

Inventor： Jian Zuo ,  Santanu Hati ,  Marisa Laura Zallocchi ,  Robert Hazlitt ,  Jaeki Min

IPC: A61K47/55 ,  A61P27/16 ,  A61K47/54

CPC classification number: A61K47/55 ,  A61K47/545 ,  A61P27/16

Abstract: Provided are CDK2-PROTAC compounds and pharmaceutical compositions thereof that can be used for specific degradation of the cyclin-dependent kinase 2 (CDK2) protein, for treatment of cancers and other CDK2 related diseases as well as for prevention and treatment of hearing loss.

公开(公告)号：US10647702B2

公开(公告)日：2020-05-12

申请号：US15812605

申请日：2017-11-14

Applicant: St. Jude Children's Research Hospital

Inventor： R. Kiplin Guy ,  Yiqun Zhang ,  Brandon Young ,  Michael Dyer ,  Kristin Finch ,  Donald Bashford ,  Nagakumar Bharatham ,  Richard Kriwacki ,  Grace Royappa ,  Lie Min ,  Jaeki Min ,  Antonio Ferreira

IPC: C07D403/06 ,  C07D403/02 ,  C07D233/22 ,  C07D403/14

Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US10525048B2

公开(公告)日：2020-01-07

申请号：US15760560

申请日：2016-09-19

Applicant: Memorial Sloan Kettering Cancer Center ,  St. Jude Children's Research Hospital

Inventor： Jaeki Min ,  Daniel C. Scott ,  Deepak Bhasin ,  Brenda A. Schulman ,  Bhuvanesh Singh ,  Jared T. Hammill ,  R. Kiplin Guy

IPC: C07D211/58 ,  A61P15/16 ,  A61P31/04 ,  A61P31/12 ,  A61K31/4468 ,  A61K31/4545 ,  C07D401/12 ,  C07D401/04 ,  C07D401/06 ,  C07D405/06 ,  C07D405/12 ,  C07D409/14 ,  C07D417/04 ,  C07D417/06 ,  C07D471/04 ,  A61K31/17 ,  A61K31/437 ,  A61K31/451 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/506

Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.